1. AstraZeneca (D5890L00011) A comparison of Symbicort® single inhaler therapy (Symbicort® Turbuhaler® 160/4.5 mcg, 1 inhalation b.i.d. plus as-needed) and conventional best practice for the treatment of persistent asthma in adults - a 26-week, randomised, open-label, parallel-group, multicentre study http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D5890L00011
2. AstraZeneca (D5890L00008) MONO: Symbicort single inhaler therapy and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults clinicaltrials.gov 2006 http://www.clinicaltrials.gov/ct/show/NCT00242411 [Accessed 12/04/2006]
3. AstraZeneca A comparison of Symbicort single inhaler therapy (Symbicort Turbuhaler160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adults - a 26-week, randomised, open-label,parallel-group, multicentre study - PASSION Study http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/8610707 Accessed July 2012
4. AstraZeneca (BN-00S-0011) Symbicort single inhaler therapy for asthma in a general practice setting http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/8610351 Accessed Jluy 2012
5. Budesonide/formoterol maintenance and reliever therapy in primary care asthma management: effects on bronchial hyperresponsiveness and asthma control;Riemersma;Primary Care Respiratory Journal,2012